An injectable depot formulation includes a biocompatible polymer, an organicsolvent combined with the biocompatible polymer to form a viscous gel, and asmall molecule drug incorporated in the viscous gel such that the formulationexhibits an in vivo release profile having Cmax to Cmin ratio less than 200and lag time less than 0.2.